Interpreting evolution of SARS-CoV-2 and other viruses

 

Jesse Bloom

Fred Hutch Cancer Center / HHMI

 

These slides at https://slides.com/jbloom/hhmi-meeting-2024

 

New variants (mutants) are always arising during viral evolution

Can we predict evolutionary success of viral variants from the biochemical effects of their constituent mutations?

SARS-CoV-2's spike binds receptor and mediates viral entry

viral membrane

cell membrane

spike

spike conformational change

Image adapted from here

ACE2

antibody

Image adapted from here

SARS-CoV-2's spike binds receptor and mediates viral entry

Deep mutational scanning to measure effects of mutations 

RBD

fluorescent ACE2

yeast

fluorescent tag on RBD

Yeast display of spike receptor-binding domain (RBD) to measure ACE2 binding

cell sorting

Deep mutational scanning: selections on libraries of mutants, read out by sequencing

Experiments identified N501Y as a mutation that increases ACE2 binding

RBD

fluorescently labeled antibody

yeast

fluorescent tag on RBD

Yeast display to measure how all RBD mutations escape antibody binding

site in RBD

antibody escape

These experiments identified mutations at E484 as causing greatest antibody escape

484

These anecdotes suggest experiments can prospectively identify mutations subsequently selected by evolution

Yeast display only measures binding, which is just part of spike's biological function

cell sorting

Viral infection is more biologically relevant measure of mutation effects

However, we are cognizant of biosafety concerns of mutating actual virus

actual SARS-CoV-2 virion: pathogen capable of spread in humans

pseudotyped lentiviral particle: not a pathogen, cannot spread in humans

actual SARS-CoV-2 virion: pathogen capable of spread in humans

pseudotyped lentiviral particle: not a pathogen, cannot spread in humans

Therefore we use pseudoviruses rather than actual replicative SARS-CoV-2

Pseudoviruses are modified viruses that can only undergo single round of infection

We need to link phenotype (spike mutant) and genotype (sequence encoded by virus)

To link genotype to phenotype link, we encode spike in viral genome with barcode

We then create genotype-phenotype linked libraries by two-step process

Result is library of spike mutant pseudoviruses with identifying barcodes

  • Captures full cell-entry function of spike
  • Each mutant identified by short barcode
  • Pseudoviruses safe at biosafety-level 2
  • Broadly applicable to viral entry proteins

Measured how spike mutations affect three molecular phenotypes

Measured how spike mutations affect three molecular phenotypes

Measured how spike mutations affect three molecular phenotypes

Neutralization by soluble ACE2 is proportional to ACE2 binding affinity

Measured how spike mutations affect three molecular phenotypes

Deep mutational scanning correlates well with traditional neutralization assays

Full workflow for measure effects of mutations on antibody neutralization

How do these experimental measurements relate to actual evolution?

Estimating variant fitness (multinomial logistic regression)

Estimating variant fitness (multinomial logistic regression)

We analyze changes in clade growth rather than raw clade growth

change in clade growth

clade growth

Deep mutational scanning measurements correlate with SARS-CoV-2 variant fitness

Combining phenotypes offers best predictions (because mutations can involve tradeoffs)

We can explain ~55% of the variance in growth of different clades, with largest fraction of variance uniquely explained by sera escape.

Can partially predict outcome of real-world evolutionary competition from experiments!

We can apply this experimental approach to many other viral entry proteins

  • SARS-CoV-2 spike
  • influenza hemagglutinin (HA)
  • HIV envelope protein
  • Lassa virus glycoprotein
  • Nipah virus RBP and F proteins
  • RSV G and F proteins
  • Rabies G protein
  • Chikungunya virus E proteins

Pseudovirus of clade 2.3.4.4b H5 HA

We prospectively identified A160T as strongly reducing neutralization by sera elicited by candidate vaccine strains

(L122Q, A160T, T199I)

(L122Q, P162Q, T199I)

A160T in recent human case (A160T is called A156T by CDC)

Bloom lab

Bernadeta Dadonaite

Kate Crawford

Caelan Radford

Tyler Starr

Allie Greaney

Rachel Eguia

William Hannon

Jenny Ahn

 

Fred Hutch Cancer Center

Trevor Bedford

John Huddleston

 

University of Washington

Helen Chu and HAARVI cohort

Neil King

David Veesler

 

Thanks

 

 

Pirbright Institute

Thomas Peacock

 

University of Pennsylvania

Scott Hensley

Louise Moncla

Jordan Ort

 

St Jude Children's Hospital

Richard Webby

 

hhmi-meeting-2024

By Jesse Bloom

hhmi-meeting-2024

From molecular phenotype to virus evolution: deep mutational scanning of the SARS-CoV-2 spike

  • 202